40 Spring 2023. Vol 32. Num 1 * Corresponding Author: Mehdi Evazalipour Address: Department of Pharmaceutcal Biotechnology, School of Pharmacy, Guilan University of Medical Sciences, Rasht, Iran. Tel: +98 (912) 2843291 E-Mail: evazalipour@gums.ac.ir Research Paper Associaton of CYP2D6*4 Polymorphism With Response to Atorvastatn in Patents With High Low-Density Lipoprotein Level in Northern Iran, Guilan Provice 1. Student Research Commitee, School of Pharmacy, Guilan University of Medical Sciences, Rasht, Iran. 2. Department of Pharmaceutcal Biotechnology, School of Pharmacy, Guilan University of Medical Sciences, Rasht, Iran. 3. Cardiovascular Diseases Research Center, Department of Cardiology Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran. 4. Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Golestan University of Medical Sciences, Gorgan, Iran. 5. Statstcal Research and Training Center, Statstcal Center of Iran, Tehran, Iran. 6. Department of Pharmacology and Toxicology, School of Pharmacy, Guilan University of Medical Sciences, Rasht, Iran. Raziyeh Asadollahpour 1, 2 , Faeze Khaghani 2 , Fardin Mirbolouk 3 , Anvarsadat Kianmehr 4 , Omid Goodarzvand 2 , Sara Dabirian 2 , Mohammad Sadegh Alipour 5 , Ehsan Zamani 6 , *Mehdi Evazalipour 2 Background People who take statns respond diferently to them due to genetc diferences. One of the most signifcant enzymes involved in drug metabolism is cytochrome P450 2D6 (CYP2D6) enzyme, coded by the CYP2D6 gene. Individuals who carry two non-functonal alleles in this gene are considered as poor metabolizers. Recognizing poor metabolizers may help prevent adverse efects of drugs. Objectve This study aims to assess the associaton of CYP2D6*4, as the most frequent non-functonal allele of CYP2D6 gene, and response to atorvastatn in patents with high low-density lipoprotein (LDL) level in northern Iran. Methods A total of 180 patents with high LDL level underwent treatment with atorvastatn for 8 weeks to assess their response. They were assessed in terms of CYP2D6*4 polymorphism using the amplifca- ton-refractory mutaton system/polymerase chain reacton method and the results were validated by the sanger sequencing method. At the end, the associaton between CYP2D6*4 allele and response to atorvastatn was assessed. Results In patents, the percentage of the CYP2D6*4 variant was 7%. This allele was not observed in homozygous patents. There was no signifcant associaton between CYP2D6*4 polymorphism and re- sponse to atorvastatn, which might be due to low frequency of CYP2D6*4 in patents. The observed allelic frequency was close to the frequency reported in previous studies for healthy Iranian people. Conclusion It seems that CYP2D6*4 polymorphism is not the cause of poor metabolism in poor metabo- lizers in northern Iran. Therefore, to diagnose poor metabolizers in this region, further studies on other genes are recommended. A B S T R A C T Keywords: Atorvastatn, CYP2D6, Polymorphism, LDL Received: 13 Apr 2022 Accepted: 23 Oct 2022 Available Online: 01 Apr 2023 Citaton Asadollahpour R, khaghani F, Mirbolouk F, Kianmehr A, Goodarzvand O, Dabirian S, et al. [Association of CYP2D6*4 Polymor- phism With Response to Atorvastatin in Patients With High Low-Density Lipoprotein Level in Northern Iran, Guilan Provice (Persian)]. Journal of Guilan University of Medical Sciences. 2023; 32(1):40-53. https://doi.org/10.32598/JGUMS.32.1.1693.2 https://doi.org/10.32598/JGUMS.32.1.1693.2 Use your device to scan and read the article online